Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022


LungFit® PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun

See the original post here:
Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022

Related Posts